---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-072598"
form_type: "8-K/A"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2024-08-26T23:59:59+00:00"
generated_at: "2026-05-31T07:43:17.056378+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# SpinCo reports $14.3M net loss for nine months; going concern uncertainty raised

## Summary
- Net loss of $14.3M for nine months ended June 30, 2024 (vs $7.5M prior year); no revenue.
- Working capital deficit of $21.4M; cash balance $0 at June 30, 2024.
- Due to related party (Citius Pharma) $30.9M, up from $19.5M at Sept 30, 2023.
- Company expresses substantial doubt about ability to continue as going concern within one year.
- Stock-based compensation expense $5.8M for the nine months; $40M in-process R&D asset for LYMPHIR.

## SEC filing metadata
- accession: 0001213900-24-072598
- form_type: 8-K/A
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2024-08-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390024072598/0001213900-24-072598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390024072598/ea0212260-8ka1_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-072598
- JSON: https://secwatch.observer/filing/0001213900-24-072598.json
- Plain text: https://secwatch.observer/filing/0001213900-24-072598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.